A study evaluating the efficacy and safety of secukinumab compared to a drug combination in patients with severe Takayasu arteritis.
- Substances:AdalimumabInfliximab+2
France- Participants:0–17 years · 18–64 years · 65+ years
- Substances:Adalimumab
Rare diseases
Investigational molecules
Locations
FranceA study of enzomenib in adult patients with relapsed or refractory acute leukemia, including those with MLL rearrangement or NPM1 mutation.
FranceN1T-MC-MALO: A Master Protocol for a Randomized, Controlled, Clinical Trial of Multiple Pharmacologic Agents in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease Who Are at Increased Risk of Developing Major Adverse Liver Outcomes (SYNERGY-Outcomes); N1T-MC-TZ01 Tirzepatide in participants with high-risk MASLD; N1T-MC-RT01 Retatrutide in participants with high-risk MASLD
FrancePhase 1b-2 Study of Elacestrant and Abemaciclib in Patients with Brain Metastases from ER-Positive, HER2-Negative Breast Cancer
FranceEfficacy and Safety of Subcutaneous Belimumab in Adults with Connective Tissue Disease-Associated Interstitial Lung Disease
FranceStudy of GSK6042981 compared to sunitinib for patients with gastrointestinal stromal tumors that spread or cannot be removed after imatinib treatment
FranceStudy comparing firmonertinib with osimertinib or afatinib for patients with advanced lung cancer with uncommon EGFR mutations
FranceA study comparing brelovitug to bulevirtide for treating chronic hepatitis delta infection in patients currently receiving bulevirtide
FranceStudy of Trastuzumab Deruxtecan Versus Chemotherapy as Additional Treatment After Surgery for Patients with HER2-Positive Endometrial Cancer
FranceA Study of Enlicitide for Safety and Effectiveness in Children and Adolescents with Heterozygous Familial Hypercholesterolemia
FranceTesting 18F-DPA-714 PET scan as a marker of brain inflammation in patients with autoimmune encephalitis
FranceA study comparing prasinezumab with placebo for people with early-stage Parkinson's disease
FranceTell us about your condition – we search every trial in Europe and connect you with the right site.